StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Pacira BioSciences's price to sales ratio was 1.9× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 1.0× to 6.3×, with a median of 1.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.9×+0.4
2025Dec 31, 20251.6×+0.3
2024Dec 31, 20241.3×−1.1
2023Dec 29, 20232.4×−0.4
2022Dec 30, 20222.7×−2.5
2021Dec 31, 20215.2×−0.9
2020Dec 31, 20206.2×+1.4
2019Dec 31, 20194.8×−0.7
2018Dec 31, 20185.5×−1.1
2017Dec 29, 20176.6×+2.2
2016Dec 30, 20164.4×−3.1
2015Dec 31, 20157.5×−11.4
2014Dec 31, 201418.8×−12.0
2013Dec 31, 201330.9×+13.6
2012Dec 31, 201217.3×+6.3
2011Dec 30, 201110.9×–

More Pacira BioSciences figures

See a number that looks wrong?